The Life Sciences Report: 17/3/15, page-25

I have provided several circumstances which taken together, indicate manipulation is highly likely. Read back and stop taking me out of context.

You would like ordinary shareholders to disregard this very real likelihood.

You also would like ordinary shareholders to not focus on the upside of MSB.
Rather you want us to quantify everything about the future of MSB with total precision.
This is absurd.

It's the scenic route to interminable discussion as guided by madamswer.

Anything, just don't talk about the upside of MSB, certainly not by analogy, context and discussion of the science.

MSB is an emerging bluechip and it's cheap right now thanks to the manipulation IMO.